New challenges, new opportunities: Next generation sequencing and its place in the advancement of HLA typing.


Journal

Human immunology
ISSN: 1879-1166
Titre abrégé: Hum Immunol
Pays: United States
ID NLM: 8010936

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 17 04 2020
revised: 29 12 2020
accepted: 18 01 2021
pubmed: 9 2 2021
medline: 5 1 2022
entrez: 8 2 2021
Statut: ppublish

Résumé

The Human Leukocyte Antigen (HLA) system has a critical role in immunorecognition, transplantation, and disease association. Early typing techniques provided the foundation for genotyping methods that revealed HLA as one of the most complex, polymorphic regions of the human genome. Next Generation Sequencing (NGS), the latest molecular technology introduced in clinical tissue typing laboratories, has demonstrated advantages over other established methods. NGS offers high-resolution sequencing of entire genes in time frames and price points considered unthinkable just a few years ago, contributing a wealth of data informing histocompatibility assessment and standards of clinical care. Although the NGS platforms share a high-throughput massively parallel processing model, differing chemistries provide specific strengths and weaknesses. Research-oriented Third Generation Sequencing and related advances in bioengineering continue to broaden the future of NGS in clinical settings. These diverse applications have demanded equally innovative strategies for data management and computational bioinformatics to support and analyze the unprecedented volume and complexity of data generated by NGS. We discuss some of the challenges and opportunities associated with NGS technologies, providing a comprehensive picture of the historical developments that paved the way for the NGS revolution, its current state and future possibilities for HLA typing.

Identifiants

pubmed: 33551127
pii: S0198-8859(21)00017-3
doi: 10.1016/j.humimm.2021.01.010
pii:
doi:

Substances chimiques

HLA Antigens 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

478-487

Informations de copyright

Copyright © 2021 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Valia Bravo-Egana (V)

Medical College of Georgia, Augusta University, Department of Surgery, 1120 Fifteenth St. BA1641, Augusta, GA 30912, USA. Electronic address: vbravoegana@augusta.edu.

Holly Sanders (H)

Augusta University Medical Center, Histocompatibility and Immunology Laboratory, 1120 Fifteenth St. BA1641, Augusta, GA 30912, USA.

Nilesh Chitnis (N)

Baylor College of Medicine, Methodist Neurosensory Building, Department of Surgery, Houston, TX 77030, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH